Clinical trial
Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors
NCT00039390 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00039390 |
|---|---|
| Title | Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Trial of ZD1839 With Capecitabine in Patients With Advanced Solid Tumors (Formerly a Phase I Trial of ZD1839 With Capecitabine and Celecoxib) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | capecitabine, gefitinib, pharmacological study, laboratory biomarker analysis |
| Enrollment | 41 |
| Start date | Apr 1, 2002 |
| Primary completion | May 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: